GT Biopharma, Inc....announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers....GTB-5550 TriKE™ was evaluated in several preclinical models overexpressing B7H3, and was found to be effective at promoting NK cell killing of multiple cancer cell types. B7H3 is over-expressed on several cancer types including non-small cell lung cancer, squamous cell carcinoma, and breast, renal, pancreatic, ovarian, liver and colorectal cancers.